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MOBILITY limitation, a common geriatric condition, affects an individual’s quality of life, health care costs, 
and resource utilization while being predictive of disability, 
risk of hospitalization, and mortality (1–5). Among the 
function promoting therapies that are being developed for 
the treatment of functional limitations, androgens are the 
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farthest in development. Testosterone levels are associated 
with skeletal muscle mass, lower extremity strength, and 
physical function (6–12). Men with low free testosterone 
are at increased risk of mobility limitation and its pro-
gression (8). Testosterone supplementation increases 
skeletal muscle mass (13–21), but its effects on muscle 
strength and physical function have been inconsistent 
across trials (13–21). Most testosterone trials have been 
conducted in healthy older men without functional limi-
tations; the safety and efficacy of testosterone in improv-
ing muscle performance and physical function have not 
been demonstrated in older individuals with mobility 
limitation.
The Testosterone in Older Men with Mobility Limita-
tions (TOM) Trial was a placebo-controlled randomized 
trial (22,23), whose aim was to determine whether tes-
tosterone therapy in older men with mobility limitation 
and low total or free testosterone levels improves lower 
extremity muscle strength and physical function (22). As 
reported recently (23), because of a significantly higher 
incidence of adverse cardiovascular events in men assigned 
to the testosterone arm, the trial’s Data and Safety Mon-
itoring Board recommended that further enrollment and 
administration of study medications to participants be 
discontinued.
Here, we evaluated the clinical meaningfulness of the 
effects of intervention on performance-based as well as 
self-reported measures of muscle performance and physical 
function in relation to participant’s perception of change. To 
determine whether changes in the measures of muscle per-
formance, skeletal muscle mass, and physical function were 
patient important and thus clinically meaningful, we cat-
egorized the participants as “improved” or “not im-
proved” based on whether the change in outcome 
exceeded the minimally important difference (MID), deter-
mined using an anchor-based method within this trial. We 
analyzed the factors associated with improvements in out-
comes and explored the relation between change in efficacy 
outcomes and adverse events.
Methods
The trial’s design and safety results have been published 
(22,23).
Study Design
The TOM Trial was a parallel group, placebo-controlled, 
double-blind randomized trial, approved by the Institutional 
Review Board of Boston University Medical Center 
(BUMC), New England Research Institutes, Watertown, 
MA, and the Boston Veterans Administration Health Care 
System (BVAHCS). Participant recruitment took place at 
BUMC, New England Research Institutes, and BVAHCS, 
but outcome assessments were performed only at BUMC. 
All participants provided written informed consent.
Eligibility Criteria
The participants were community-dwelling men, aged 
65 years and older, with total testosterone between 100 and 
350 ng/dL or free testosterone less than 50 pg/mL, and 
mobility limitation. The participants were deemed to have 
mobility limitation if they reported difficulty walking two 
blocks on a level surface or climbing 10 steps and had a 
summary score between 4 and 9 on the Short Physical 
Performance Battery (3), which reflects moderate-to-mild 
degree of physical dysfunction.
We excluded men who had prostate cancer, lower urinary 
tract symptom score greater than 21, prostrate specific antigen 
greater than 4 ng/mL, unstable angina, congestive heart failure, 
myocardial infarction within 3 months, uncontrolled hyper-
tension, neuromuscular diseases that limited mobility, alanine 
or aspartate aminotransferase concentrations more than three 
times the upper limit of normal, creatinine more than 3.5 mg/
dL, hemoglobin A1c more than 8.5%, hematocrit more than 
48%, untreated severe obstructive sleep apnea, or body mass 
index more than 40 kg/m2. Men using testosterone, growth 
hormone, or any anabolic therapy or drugs that affect gonadal 
function were excluded.
Randomization and Blinding
Eligible participants were randomized to either placebo 
or testosterone gel using a concealed computer-generated 
randomization table and a block size of 6. Participants were 
stratified by age (65–75 and >75 years). The participants 
and outcome assessors were blinded to intervention.
Study Intervention
The participants applied daily transdermal gel containing 
either placebo or 100 mg testosterone (Testim 1%; Auxilium 
Pharmaceuticals, Norristown, PA (24)) for 6 months. This 
regimen of testosterone gel raises total testosterone concen-
tration into the mid-to-high normal range in hypogonadal 
men (24). To maintain blinding, all participants applied daily 
three tubes of the gel that were identical in appearance; those 
assigned to testosterone group applied two tubes each con-
taining 5 g testosterone gel (containing 50 mg testosterone) 
plus one tube containing placebo gel; and those assigned to 
placebo group received three tubes containing placebo that 
were identical in appearance to the tubes containing testoster-
one. Testosterone was measured 2 weeks after randomization 
in blood samples drawn 2–4 hours after gel application. If the 
average of the two testosterone concentrations was less than 
500 ng/dL or more than 1,000 ng/dL, the unblinded physician 
either increased the daily dose to 15 g or decreased it to 5 g.
Outcomes
The primary outcome was change in maximal voluntary 
strength in the leg-press exercise assessed by the one-repetition 
maximum (1-RM) method (16,22,25) using pneumatic 
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resistance machines (Keiser Sport, Fresno, CA). Leg-press 
strength is important for activities of daily living such as 
walking and climbing stairs and decreases with advancing 
age (26,27). Following a 5-minute warm-up, loads were 
progressively increased until 1-RM, the maximum amount 
of weight a participant could lift, was achieved. This proce-
dure was also performed for the seated chest-press exercise. 
Both tests were repeated within 7 days of the initial test.
Physical function was assessed using a 12-step stair-
climb, 40-m walk, and a lift-and-lower task (22–25). The 
stair-climb and walk tests were performed with and without 
a load equal to 20% body weight. Participants completed 
two trials of the stair-climb and walk as quickly as possible 
without running. Walking speed was recorded using a 
switch mat and infrared timing system (22–25). Stair-climb 
test required participants to complete two trials of the 
12-step staircase ascent as quickly as possible (22–25). 
Stair-climbing power was calculated as the product of body 
weight plus weight carried, total stair-rise, divided by 
ascent time. In the lift-and-lower task, participants com-
pleted two trials of lifting and lowering a basket holding 
a weight equivalent to 15% body weight. The number of 
shelves completed was recorded.
Lean body mass (LBM) and appendicular lean soft 
tissue (ALST) mass were determined using dual-energy 
x-ray absorptiometer (Hologic QDR 4500A), calibrated 
using a soft tissue phantom (28). ALST was calculated as the 
sum of the lean masses of the upper and lower extremities.
Self-reported function and disability were measured 
using Late-Life Function and Disability Index (29). Fatigue 
was measured using Chalder Fatigue Scale (30).
Measures of muscle performance and physical function 
were assessed at baseline and during Week 24. Body 
composition and self-reported measures were assessed at 
baseline and Weeks 12 and 24. For participants whose study 
medication was discontinued because of trial’s cessation, 
the efficacy outcomes were assessed at intervention discon-
tinuation, if possible.
Participants with limited exercise tolerance or those at 
high risk of cardiovascular events underwent a modified 
testing protocol, which used outcomes that do not elicit 
greater cardiovascular stress than activities of daily living (22). 
All others underwent a cardiopulmonary exercise tolerance 
test to assess evidence for ischemia or exercise intolerance and 
underwent exercise testing consistent with exercise tolerance 
test (Figure 1).
Minimally Important Difference
The anchor-based MID was estimated for each outcome 
by comparing it against a global rating provided by each 
participant at the 6-month visit (31; A.M. Jette, N. Latham, 
S. M. Haley, et al., unpublished data, 2011). Participants 
rated their perception of change in each outcome over the 
previous 6 months. Participants were grouped into two cat-
egories based on response to global rating on each outcome: 
better (those who responded as completely recovered, re-
covered, much better, or better) and no change or worse 
(those who responded no better, worse, or much worse). 
A receiver operating curve compared participants who 
rated their strength and physical function as “better” at 6 
months to those reporting “no change or worse” by examining 
the mean raw score change on each outcome measure from 
baseline to 6 months to the global measure of change in func-
tion (31; A.M. Jette, N. Latham, S. M. Haley, et al., unpublished 
data, 2011). We computed the mean MID and percentage of 
participants whose change from baseline exceeded the MID. 
The MID was calculated as the mean raw score change in 
“better” group, and we computed the percentage of partici-
pants whose change from baseline exceeded the MID.
Hormone Assays
Total testosterone level was measured at Quest Diagnostics, 
San Juan Capistrano, CA, using a Bayer-Advia-Centaur im-
munoassay with sensitivity 10 ng/dL (32). Sex hormone binding 
globulin levels were measured using an immunofluorometric 
assay with sensitivity 2.5 nmol/L (DELFIA-Wallac, Turku, 
Finland) (8,13,23). Free testosterone was calculated using a 
published law of mass action equation (33).
Statistical Analyses
The planned sample size of 252 participants was based 
on Type I error of 0.05, 90% power, and assumption of 25 kg 
difference in the change in leg-press strength (SD 55 kg) 
(23,34). When the data and safety monitoring board recom-
mended enrollment cessation, 209 men had been randomized. 
Because of participant withdrawal and the early stopping of 
the trial, a number of participants had missing outcomes data, 
and in some participants, outcomes data were obtained at an 
earlier time than the planned 6 months of intervention. The 
primary analysis included all participants with a baseline and 
at least one postrandomization measurement (“intention-to-treat 
[ITT] sample”). This was supplemented by a “per-protocol” 
analysis restricted to participants who had completed 6 months 
of study medication (“completion sample”).
Exploratory analyses were conducted using tabular and 
graphical summaries obtained via generalized additive 
models. Change in each outcome measure was calculated 
for each participant and compared across study arms via 
Fisher’s exact and Student’s t tests. We categorized partici-
pants as “improved” or “not improved” depending on 
whether their change from baseline equaled or exceeded the 
MID estimates. The proportion of participants “improved” 
in the two arms was compared using Fisher’s exact tests. 
The associations between baseline levels and changes in 
LBM and ASLT and total and free testosterone levels and 
changes in muscle performance and physical function mea-
sures were evaluated using generalized additive models and 
Spearman’s rank correlation statistics. Sensitivity analyses 
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were conducted using multiple linear and logistic regres-
sion models.
As the trial was designed with a primary outcome in 
mind and was stopped early reducing statistical power, 
no adjustment for multiple comparisons was performed. 
Results therefore deemphasized hypothesis testing in favor 
of estimation of effects and comparison of differences vis-
à-vis the calculated MID.
Results
Flow of Participants Through the Study
The details of the study have been published (23). Briefly, 
when data and safety monitoring board recommended ces-
sation of further enrollment, 4,726 men had been screened, 
278 had met eligibility criteria, and 209 had been random-
ized, 106 to testosterone, and 103 to placebo. Hundred and 
twenty-eight men completed all phases of the study, and 10 
men had completed the 6-month intervention phase; these 
138 participants constituted the completion sample. An 
additional 27 men had undergone at least one postrandom-
ization assessment (Figure 1). These 165 men constituted 
the ITT sample.
Baseline Characteristics
Table 1 shows the baseline characteristics of the ITT and 
completion samples. The mean (SD) age of the ITT sample 
was 74 (5.4) years. The mean (SD) Short Physical Perfor-
mance Battery score of 7.7 (1.4) indicates a moderate level 
of physical dysfunction. Fifty-four percent of men had 
walking speed less than 1.0 m/s.
Compliance
Participants using more than 90% of the prescribed 
gel tubes were deemed compliant. The proportion of men 
compliant by this criterion exceeded 90% in both groups 
(23).
Assessed for Eligibility by Phone Screen= 4,726
* Excluded for not meeting inclusion criteria = 2,698
* Excluded because refused to participate = 239
* Excluded for other reasons = 549
Total number excluded = 3,486
Eligible for In-Person Screen  = 1,240
Did not sign consent = 669
Randomized  = 209 
Assigned to Testosterone = 106 Assigned to Placebo = 103 
Signed consent  = 571
Failed in-person screen = 293
Dropped out before randomization = 69
Group A = 32 Group B = 10 Group C = 64 Group A = 30 Group B = 8 Group C = 65 
Completed study = 19 
Did not complete 
study, but completed 
treatment = 3 
Did not complete 
treatment, but 
completed midpoint 
assessment = 3 
Did not reach midpoint 
assessment = 7 
Completed study = 5 
Did not complete 
study, but completed 
treatment = 0 
Did not complete 
treatment, but 
completed midpoint 
assessment = 3 
Did not reach midpoint 
assessment = 2 
Completed study = 38 
Did not complete 
study, but completed 
treatment = 3 
Did not complete 
treatment, but 
completed midpoint 
assessment = 8 
Did not reach midpoint 
assessment = 15 
Completed study = 48 
Did not complete 
study, but completed 
treatment = 3 
Did not complete 
treatment, but 
completed midpoint 
assessment = 6 
Did not reach midpoint 
assessment = 8 
Completed study = 5 
Did not complete 
study, but completed 
treatment = 0 
Did not complete 
treatment, but 
completed midpoint 
assessment = 2 
Did not reach midpoint 
assessment = 1 
Completed study = 13 
Did not complete 
study, but completed 
treatment = 1 
Did not complete 
treatment, but 
completed midpoint 
assessment = 7 
Did not reach midpoint 
assessment = 9 
ITT Sample = 82
Per-Protocol Analytic Sample = 68
ITT Sample =  85
Per-Protocol Analytic Sample = 70
Figure 1. The flow of participants through the TOM Trial is depicted. A two-stage screening process was used. Of 4,726 participants who underwent telephone screen-
ing, 1,240 were deemed eligible for further screening, 571 signed consent and were screened in person, 278 met eligibility criteria, and 209 were randomized. Participants 
with limited exercise tolerance or those at high risk of cardiovascular events underwent a modified testing protocol, which included unloaded 40-m walk test, Bassey’s 
leg power, physical activity, and self-reported measures (Group A). All others underwent a cardiopulmonary exercise tolerance test. Participants who demonstrated 
evidence of ischemia or exercise intolerance during exercise tolerance test were assigned to Group B and underwent loaded and unloaded walk and stair-climb, leg-press 
strength and power, and self-reported measures. Participants who underwent an exercise tolerance test without demonstrating ischemic changes underwent complete 
battery of tests, including loaded and unloaded walk and stair-climb, lift and reach, leg press and chest press, physical activity, and self-reported measures (Group C).
TRAVISON ET AL.1094
Testosterone Levels
Total and free testosterone levels increased significantly 
more in testosterone arm than in placebo arm (Supplementary 
Table 1).
Efficacy Outcomes
The increase in leg-press strength was greater in men 
assigned to testosterone arm than in those assigned to pla-
cebo arm, whether the change is expressed on a proportion-
ate or an absolute scale (Figure 2); results were similar in 
the completion sample (not shown). The percent of men 
whose leg-press strength improved more than the MID was 
significantly greater in the testosterone group (43%) than in 
the placebo group (18%, p = .01; Figure 2). The men whose 
leg-press strength improved more than the MID did not dif-
fer significantly in their baseline body composition, muscle 
performance, or physical function from those who improved 
less than the MID (not shown). Among participants assigned 
to testosterone arm, increases in total and free testosterone 
were associated with increased leg-press strength, appen-
dicular skeletal muscle mass, and loaded stair-climb power 
(Supplementary Table 2). Lean mass gains and fat mass 
losses were significantly greater in the testosterone than in 
the placebo arm (Table 2).
The proportion of men whose chest-press strength 
improved more than the MID was greater in the testosterone 
group than in the placebo group (Figure 2). Changes in chest- 
press strength were associated with changes in total (r = .34, 
p = .002) and free testosterone (r = .36, p = .001) and changes 
in LBM (r = .42, p = .0001) and ALST (r = .36, p = .001).
A greater proportion of men randomized to testosterone 
arm improved more than the MID in their loaded stair-
climbing power than those randomized to placebo (p = .03); 
those achieving the MID exhibited significantly greater in-
creases in total and free testosterone, LBM and ALST, and 
leg-press and chest-press strengths but did not differ in 
baseline measures (not shown). Changes in loaded stair-
climbing power were significantly related to changes in 
total and free testosterone, LBM and ALST, and leg-press 
strength (Supplementary Table 2).
Changes in unloaded walking speed and unloaded stair- 
climbing did not differ significantly between the two groups. 
However, changes in loaded walking speed and loaded 
stair-climbing power tracked with changes in leg-press 
strength (Supplementary Table 2).
The self-reported measures of functional disability and 
fatigue and physical activity counts did not differ between 
arms (Figure 2).
Treatment Effect Sizes
The differences between testosterone and placebo groups 
for leg and chest press, lean mass and ASLT, and physical 
function measures ranged from 0.25 to 0.35 SD units 
(Figure 3).
Relation of Cardiovascular Adverse Events to Treatment 
Responsiveness
As reported previously (23), cardiovascular-related 
adverse events occurred in 28 participants (23 in testoster-
one and 5 in placebo arm); of these, 22 (17 testosterone and 
Table 1. Baseline Characteristics of the Participants Included in the Efficacy Analyses
ITT Sample (N = 165) Completer Sample (N = 138)
Testosterone (n = 82) Placebo (n = 83) Testosterone (n = 69) Placebo (n = 69)
Age, y 73.6 ± 5.8 74.1 ± 5 73.8 ± 5.8 73.9 ± 4.9
Body mass index, kg/m2 29.6 ± 3.9 29.9 ± 4.2 29.2 ± 4 30.1 ± 4.4
Total testosterone, nmol/L* 8.6 ± 2.1 8.2 ± 2.3 8.7 ± 2.2 8.0 ± 2.3
Free testosterone, pmol/L† 165.4 ± 40.2 141.8 ± 44.0
Lean body mass, kg‡ 55.1 ± 6.9 56.5 ± 6.5 (81) 54.5 ± 7 (69) 57 ± 6.8 (67)
ASLT, kg‡ 23.7 ± 3.3 24.1 ± 3 (81) 23.4 ± 3.4 (69) 24.3 ± 3.2 (67)
SPPB score 7.7 ± 1.4 7.7 ± 1.4 7.6 ± 1.5 (69) 7.6 ± 1.5 (69)
Leg-press strength, N‡ 1913.9 ± 431.4 (59) 1968.8 ± 346.9 (60) 1908.9 ± 405.6 (51) 1971.7 ± 336.9 (49)
Chest-press strength, N‡ 417.8 ± 100 (52) 421.2 ± 87.9 (53) 418.1 ± 95.4 (45) 428.3 ± 90.3 (45)
Leg-press power, W‡ 499.5 ± 160.3 (58) 507.7 ± 133.5 (59) 491.5 ± 150.3 (50) 513.1 ± 123.9 (49)
Chest-press power, W‡ 161.9 ± 43.7 (52) 163.7 ± 43.2 (52) 159.4 ± 41.3 (45) 167.3 ± 44.8 (45)
Dominant hand grip strength, kg‡ 27.6 ± 6.9 (75) 26.5 ± 7.6 (75) 27.6 ± 6.7 (62) 26.2 ± 8 (61)
Unloaded 40-m walking speed, m/s‡ 1.7 ± 0.4 (72) 1.7 ± 0.4 (76) 1.6 ± 0.4 (60) 1.7 ± 0.4 (63)
Loaded 40-m walking speed, m/s‡ 1.6 ± 0.4 (55) 1.6 ± 0.4 (57) 1.6 ± 0.4 (49) 1.7 ± 0.4 (46)
Unloaded stair-climb power, W‡ 322.9 ± 114.6 (57) 322 ± 92.1 (58) 312.8 ± 112.9 (50) 324.1 ± 86.9 (47)
Loaded stair-climb power, W‡ 353.3 ± 138.2 (55) 348.8 ± 116.3 (56) 346.7 ± 134.9 (49) 357.7 ± 109.7 (46)
Lift–lower score‡ 25.2 ± 9 (50) 23.6 ± 10.1 (51) 25.2 ± 8.7 (44) 23.1 ± 10.2 (43)
Late Life Functional Disability Index 60.5 ± 9.6 (67) 62.6 ± 10.2 (68) 61.2 ± 9.9 (56) 61.7 ± 9.1 (55)
Fatigue score 4.9 ± 3.1 (77) 4.2 ± 3.2 (77) 4.8 ± 3.1 (64) 4.2 ± 3.3 (65)
Notes: ALST = appendicular lean soft tissue; ITT = intention-to-treat; and SPPB = Short Physical Performance Battery.
* Measured in a single morning sample drawn between 7 and 11 am.
†
 Calculated via mass action equation.
‡
 Number of nonmissing records shown in parentheses.
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Figure 2. The percent change from baseline in selected measures of muscle performance and physical function in testosterone and placebo arms of the trial. Data 
are mean and 95% confidence intervals. Estimates of mean treatment difference attributable to testosterone administration (∆TP) are presented along with 95% confi-
dence intervals. These may be interpreted as estimates of difference (testosterone minus placebo) in proportionate change achieved over 6 months.
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mass, and loaded stair-climbing power than those assigned 
to placebo. Because of early trial cessation, the preplanned 
enrollment target of 252 randomized men was not met; fur-
thermore, a substantial fraction of randomized participants 
did not complete the planned 6 months of intervention. In 
spite of the early cessation of enrollment and earlier than 
planned discontinuation of intervention in many partici-
pants, changes in muscle strength and stair-climbing power 
associated with randomization to testosterone arm of the 
study were statistically significant. As a greater proportion 
of men experienced improvements in leg-press and chest-
press strengths and stair-climbing power that exceeded the 
MID, these treatment effects are patient important and 
therefore clinically meaningful. Walking speed, a key 
determinant of mobility, did not change significantly. The 
improvements in muscle mass and strength without signifi-
cant improvements in walking speed should be weighed 
against the greater risk of adverse cardiovascular events 
observed among men assigned to testosterone arm.
The changes in maximal voluntary strength and loaded 
stair-climbing power were related to changes in testosterone 
concentrations. The muscle strength gains were related to 
gains in skeletal muscle mass, which were related to changes 
in total and free testosterone concentrations. Changes in 
stair-climbing power and walking speed were related to 
changes in leg-press strength, which is an important deter-
minant of stair-climbing power and walking speed. These 
correlational analyses are consistent with the following 
mechanistic directionality: increases in testosterone levels → 
gains in skeletal muscle mass → increase in muscle strength → 
improved physical function.
Meta-analyses of testosterone trials have reported signifi-
cant gains in LBM but inconsistent changes in muscle 
strength and physical function (35,36). The trials in these 
meta-analyses were limited by the small number of partici-
pants, shorter treatment durations than the 6-month inter-
vention period used in the TOM Trial, or the failure to 
include comprehensive assessments of muscle strength and 
5 placebo) were included in the ITT sample. There were no 
significant differences between these participants and others 
for any outcome, although the statistical power for these 
comparisons was limited due to the small number of par-
ticipants with adverse events.
Discussion
In this population of older men with mobility limitations 
and high burden of chronic diseases, the men assigned to 
the testosterone arm experienced greater gains in leg-press 
strength, chest-press strength and power, skeletal muscle 
Table 2. Changes in Measures of Skeletal Muscle Mass and Fat Mass by Dual-Energy x-Ray Absorptiometer
Body Composition  
Measurement (kg)
Testosterone, Mean ± SD Placebo, Mean ± SD
Treatment Difference, 
Midtreatment
Treatment Difference, 
Posttreatment
Baseline Midtreatment Posttreatment Baseline Midtreatment Posttreatment Mean(CI) p Mean(CI) p
ITT sample (N = 82) (N = 73) (N = 77) (N = 81) (N = 75) (N = 80)
 Total lean mass 55.1 ± 6.9 57.2 ± 7.1 56.1 ± 6.9 56.5 ± 6.5 56.7 ± 6.2 56.2 ± 6.3 1.8 (1.2, 2.5) .2 1.5 (0.4, 2.2) <.0001
 Total fat mass 26.2 ± 7.5 24.9 ± 7.1 24.0 ± 6.8 28 ± 8.4 28 ± 8.1 27.5 ± 7.9 −1.7 (−2.7, −0.6) .002 −2.0 (−2.8, −1.2) <.0001
 ASMM 23.7 ± 3.3 24.7 ± 3.3 24.2 ± 3.3 24.1 ± 3 24.1 ± 3 23.9 ± 3.1 1.1 (0.7, 1.5) <.0001 0.9 (0.4, 1.4) .0009
 Appendicular  
  fat mass
9.7 ± 2.8 9.3 ± 2.8 8.9 ± 2.6 10.7 ± 3.5 10.6 ± 3 10.5 ± 3 −0.3 (−0.6, −0.01) .04 −0.8 (−1.2, −0.4) .0003
Completion sample (N = 69) (N = 62) (N = 69) (N = 67) (N = 63) (N = 68)
 Total lean mass 54.5 ± 7 56.7 ± 7.2 55.7 ± 7.1 57 ± 6.8 57.1 ± 6.5 56.5 ± 6.6 2.0 (1.3, 2.8) <.0001 1.6 (0.8, 2.4) <.0001
 Total fat mass 25.6 ± 7.4 24.1 ± 6.9 23.5 ± 6.6 28.5 ± 8.6 28.7 ± 8.1 28.1 ± 8 −1.9 (−3.1, −0.6) <.0001 −2.2 (−1.4, −3.1) <.0001
 ASMM 23.4 ± 3.4 24.5 ± 3.4 24.2 ± 3.4 24.3 ± 3.2 24.3 ± 3.1 24 ± 3.3 1.2 (0.8, 1.6) <.0001 1.0 (0.4,1.5) .0004
 Appendicular  
  fat mass
9.5 ± 2.9 9.1 ± 2.8 8.7 ± 2.6 10.9 ± 3.6 10.8 ± 3.1 10.7 ± 3 −0.4 (−0.7,− 0.04) .02 −0.8 (−1.2, −0.4) .0003
Notes: ASMM = appendicular skeletal muscle mass; CI = confidence interval; ITT = intention to treat.
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Chest Press Power
Total LM
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Figure 3. Absolute treatment differences (testosterone vs placebo arms) are 
plotted for the primary and secondary outcomes in units normalized to the base-
line standard deviation of measurement; point estimates (red) are accompanied 
by 95% confidence intervals.
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physical function. Some trials used small doses of testoster-
one that resulted in significantly smaller increments in 
testosterone levels than were achieved in the TOM Trial 
(18,19). A unique aspect of this trial is the use of MID esti-
mates derived using an anchor within this trial to determine 
the clinical meaningfulness of the observed treatment 
effects. Additionally, the trial included a comprehensive 
assessment of upper and lower extremity function and per-
formance-based as well as self-reported measures.
Most testosterone trials have enrolled healthy older men; 
this is the first randomized testosterone trial in older men 
with mobility limitations. A recent important testosterone 
trial in older men with frailty reported improvements in 
LBM and some self-reported measures of physical function, 
but the trial found no significant differences in muscle 
strength or performance-based measures of physical func-
tion between placebo and testosterone arms (14). A signifi-
cant fraction of participants in that trial were prefrail. 
Another trial in frail elderly men also failed to find signifi-
cant improvement in muscle strength or physical function 
measures (37); the testosterone dose in that trial was lower 
than that used in the TOM Trial. Small testosterone trials in 
men with congestive heart failure have suggested improve-
ments in exercise capacity with inconsistent changes in 
muscle mass and strength (38).
In spite of substantial gains in muscle mass and maximal 
voluntary strength in men assigned to testosterone arm, 
several measures of physical function did not improve sig-
nificantly beyond the improvements seen in the placebo 
arm. Other factors, such as neuromuscular integration and 
functional training, might be required to optimize the 
translation of muscle mass and strength gains into im-
proved physical function. It is possible that neuromuscular 
adaptations that result in improved function may require 
more time than the 6-month duration of our trial. Page and 
colleagues reported significant improvement in a continu-
ous timed physical performance test after 12 months of 
testosterone administration (20), but other studies of 1- to 
3-year duration (17–19) have failed to note improvements 
in functional measures.
In our trial, treatment effects for most measures of physical 
function favored testosterone administration; in general, the 
measures having the highest ceiling (loaded stair-climb and 
loaded gait speed) showed greater testosterone effect than 
unloaded tests with lower ceilings. As substantial numbers 
of randomized participants did not complete the trial due 
to early study cessation, this may have reduced statistical 
power. However, close examination of proportional gains in 
functional outcomes indicates that variation in the unloaded 
functional measures was comparable to that in the strength 
indices. Thus, there were indeed gains in the functional 
measures among participants in the testosterone arm, but 
there were comparable gains in function among participants 
assigned to placebo (whereas participants assigned to pla-
cebo evinced little to no gains in strength; Figure 2). Thus, 
the estimated treatment effects (testosterone vs placebo) for 
unloaded walk, unloaded stair-climb, and late life function 
and disability index were of modest magnitude. By contrast, 
proportionate variation in the loaded functional measures—
particularly stair-climb power—was somewhat greater 
than that in the strength measures, so that sizeable esti-
mates of treatment effect (testosterone vs placebo) did not 
achieve statistical significance due to the large variation. 
One may postulate that had the trial achieved full enroll-
ment, these differences in the loaded measures would have 
achieved statistical significance, whereas the available evi-
dence suggests that the unloaded measures would have 
failed to demonstrate efficacy even under full enrollment.
Several factors merit consideration in weighing the observed 
improvements in muscle strength and physical function 
against the increased risk of cardiovascular events in men 
assigned to the testosterone arm. The number needed to 
treat has been used to describe the efficacy of health care 
interventions. In the TOM Trial, the numbers needed to 
treat to achieve clinically meaningful improvements in 
leg-press strength and stair-climbing power were 4.0 and 
5.5, respectively. However, the gains in skeletal muscle 
mass and muscle strength were not associated with signifi-
cant improvements in walking speed. Adjunctive strategies, 
such as physical activity or other interventions (39), may be 
needed to induce neuromuscular, cognitive, and behavioral 
adaptations that are necessary for translating muscle mass 
and strength gains induced by testosterone into functional 
improvements. Also, the testosterone administration at the 
dose used in the trial was associated with adverse events. 
Therefore, the clinical application of testosterone as a 
function promoting anabolic therapy might be predicated 
upon strategies, which augment the anabolic effects of tes-
tosterone and facilitate translation of testosterone-induced 
gains in muscle mass and strength into functional improve-
ments at lower testosterone concentrations that can be 
safely administered. Such strategies, which might include 
physical activity interventions (39), resistance exercise 
training, cognitive and behavioral training, or combined 
administration of testosterone with other anabolic agents, 
such as recombinant human growth hormone, should be 
investigated.
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